Clinical Trial

Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This phase 1/2 first-in-human study is designed to test the safety and efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a single agent and in combination with other therapies in HLA-A\*02:01-positive participants with selected advanced PIWIL1-Positive cancers.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-02-17; most recent amendment 2026-01-26.
Trial Details
NCT Number NCT06840119
Lead Sponsor Immunocore Ltd
Conditions Cancer, HLA-A*02:01-positive
Enrollment 600 participants
Start Date 2024-01-10
Primary Completion 2026-11-30 (estimated)
Study Completion 2027-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-28